（文章来源：证券日报） 证券日报网讯科拓生物8月7日在互动平台回答投资者提问时表示，目前公司与深圳未知君生物科技有限 公司正有序推进研究开发益生菌新药项目工作，公司会根据进展情况及时进行信息披露。 ...

Core Insights - Kintor Pharmaceutical (300858.SZ) provides R&D services to clients, and its animal bifidobacterium lactis strain ProSci-246 has been applied to the company's ready-to-eat probiotic products, which are now available for sale [1] Company Summary - Kintor Pharmaceutical has successfully integrated the ProSci-246 strain into its product line, indicating a step forward in its probiotic offerings [1] - The launch of these ready-to-eat probiotic products marks a significant milestone for the company, showcasing its capabilities in R&D and product development [1] Industry Context - The application of advanced probiotic strains like ProSci-246 reflects the growing trend in the health and wellness industry towards innovative and functional food products [1] - The market for ready-to-eat probiotic products is expanding, driven by increasing consumer awareness of gut health and the benefits of probiotics [1]

Summary of Key Points from the Conference Call of Ketaobiotech Company Overview - Ketaobiotech's main business segments include compound food additives and probiotics, with probiotics currently being the primary growth driver as the compound food additives segment has shrunk to about 10% of revenue due to declining sales of long-life yogurt [2][3]. Core Business Insights - The probiotics business has shown an annual growth rate exceeding 20%, significantly higher than the industry average, and the company continues to gain market share [2][3]. - The domestic probiotics market is nearing 100 billion, with a growth rate of approximately 20% over the past few years. The marketing of weight loss benefits is expected to drive industry growth in 2025 [2][5]. - Ketaobiotech holds a 7% stake in Wuka Laboratory, which is projected to achieve revenues of 1 billion in 2025, benefiting from the weight loss marketing strategy [2][7]. Market Dynamics - The probiotics market is dominated by foreign brands, with DuPont holding a 50% market share, while domestic brands account for only about 10%. This presents a significant opportunity for domestic brands like Ketaobiotech to capture market share [6][12]. - The company’s stock price has surged due to rapid growth in the probiotics sector and advancements in innovative drugs, including a clinical trial approval for a cancer treatment [7][8]. Competitive Advantages - Ketaobiotech's core competitive advantages include strong technical barriers, a rich resource library of 32,000 strains of lactic acid bacteria, and a solid clinical validation system [4][9][15]. - The company has established multiple collaboration models, including direct sales of bacterial powder, ODM/OEM custom production, and proprietary brand sales, which cater to diverse customer needs [4][16]. Future Growth Projections - Ketaobiotech is expected to achieve approximately 440 million in revenue in 2025, with a growth rate of 45%, primarily driven by the rapid growth of edible probiotics and microbial preparations for plants and animals [4][22]. - The company plans to expand production capacity, with new facilities expected to contribute an additional 500-800 million in revenue once fully operational [20][21]. Challenges and Opportunities - Domestic brands face challenges such as R&D barriers, production technology, and intellectual property issues, but the increasing demand for domestic raw materials due to trade tensions presents opportunities for Ketaobiotech [12][14]. - The company is actively pursuing international market opportunities and domestic replacement strategies, aiming to increase market share and drive growth [20][23]. New Product Developments - Ketaobiotech is launching several new products aimed at the consumer market, including "Cocoa Tribute," which is expected to generate significant revenue [24]. Conclusion - Ketaobiotech is well-positioned for future growth in the probiotics market, leveraging its competitive advantages, expanding its product offerings, and capitalizing on market trends and consumer demands [8][13].

New Stock Issuance - The new stock issuance for Zhigao Machinery (证券代码: 920101) is priced at 17.41 CNY per share, effective from August 5, 2025[1] - China Heavy Industry (证券代码: 601989) has a cash option declaration period from August 13, 2025[1] - China Shipbuilding (证券代码: 600150) has a buyback request period from August 13 to August 15, 2025[1] Offer and Acquisition Periods - Shenkou Co., Ltd. (证券代码: 002633) has a tender offer period from July 29 to August 27, 2025[1] - ST Kelly (证券代码: 300326) has a tender offer period from July 17 to August 15, 2025[1] - Happiness Blue Ocean (证券代码: 300528) has a significant announcement on July 30, 2025[1] Market Volatility - There are reports of severe abnormal fluctuations for Tibet Tourism (证券代码: 600749) as of July 31, 2025[1] - ST Suwu (证券代码: 600200) also reported significant volatility on July 30, 2025[1] - The stock of ST YaTai (证券代码: 000691) is under observation for abnormal trading activities as of August 5, 2025[1]

Group 1 - The Helicobacter pylori concept sector declined by 0.50%, ranking among the top declines in concept sectors, with notable declines in stocks such as Keta Bio, Anglikang, and Asia-Pacific Pharmaceutical [1][2] - Among the 49 stocks in the Helicobacter pylori concept sector, 27 stocks saw price increases, with Zhongheng Group, Hanyu Pharmaceutical, and *ST Sansheng leading the gains at 9.85%, 5.63%, and 5.05% respectively [1][4] - The Helicobacter pylori concept sector experienced a net outflow of 1.725 billion yuan in main funds, with Hanyu Pharmaceutical seeing the largest outflow of 909.33 million yuan [2][3] Group 2 - The top gainers in the concept sectors included the Armament Reorganization concept at 6.12%, PEEK materials at 4.11%, and Brain-Computer Interface at 2.72% [2] - The main funds saw inflows in stocks such as Zhongheng Group, Baicheng Pharmaceutical, and Asia Treasure Pharmaceutical, with inflows of 88.23 million yuan, 63.86 million yuan, and 19.51 million yuan respectively [2][4] - The stocks with the largest net outflows in the Helicobacter pylori concept included Asia-Pacific Pharmaceutical at -8.16%, Keta Bio at -10.28%, and Anglikang at -9.46% [2][3]

Group 1: Chemical Sector Performance - The chemical index and oil index primarily experienced a decline, while the chemical machinery index and chemical pharmaceutical index saw increases [1] - The chemical raw materials index fell by 1.60%, the chemical machinery index rose by 1.066%, the chemical pharmaceutical index increased by 5.11%, and the pesticide and fertilizer index dropped by 2.05% [1] - In the oil sector, the oil processing index decreased by 3.82%, the oil extraction index fell by 2.09%, and the oil trading index declined by 2.83% [1] Group 2: Oil Price Trends - International crude oil prices initially rose and then fell, with the overall average price significantly higher than the previous week [1] - As of August 1, the WTI crude oil futures settled at $67.33 per barrel, up 3.33% from July 25, while Brent crude oil futures settled at $69.67 per barrel, up 1.80% from July 25 [1] Group 3: Petrochemical Product Price Changes - The top five petrochemical products with price increases included liquid chlorine up 12.72%, soft foam polyether up 10.42%, epoxy chloropropane up 8.84%, coke up 8.06%, and epoxy propane up 7.47% [1] - The top five petrochemical products with price declines included methyl acrylate down 5.88%, natural rubber down 5.77%, battery-grade lithium carbonate down 5.48%, butadiene rubber down 4.78%, and butadiene down 4.71% [1] Group 4: Capital Market Performance of Chemical Companies - The top five listed chemical companies with the highest stock price increases were Upwind New Materials up 39.37%, Honghe Technology up 22.07%, Songjing Co. up 19.97%, Ketaobiotech up 18.88%, and Asia-Pacific Industry up 17.43% [2] - The top five listed chemical companies with the largest stock price declines were Poly United down 16.35%, Weike Technology down 13.75%, Gaozheng Mining down 13.75%, New Tide Energy down 12.99%, and Yahua Group down 11.80% [2]

证券代码：300858 证券简称：科拓生物 公告编号：2025-026 北京科拓恒通生物技术股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的具体情况 2、公司未发现近期公共传媒报道了可能或已经对公司股票交易价格产生较 大影响的未公开重大信息； 3、近期公司经营情况及内外部经营环境正常，未发生重大变化； 4、经核查，公司、控股股东和实际控制人不存在关于本公司的应披露而未 披露的重大事项，或处于筹划阶段的重大事项； 5、经核查，公司控股股东、实际控制人在公司股票交易异常波动期间不存 在买卖公司股票的行为。 三、公司是否存在应披露而未披露信息的说明 本公司董事会确认，本公司目前没有任何根据《深圳证券交易所创业板股票 上市规则》等有关规定应予以披露而未披露的事项或与该事项有关的筹划、商谈、 意向、协议等；董事会也未获悉本公司有根据《深圳证券交易所创业板股票上市 规则》等有关规定应予以披露而未披露的、对本公司股票及其衍生品种交易价格 产生较大影响的信息；公司前期披露的信息不存在需要更正、补充之处。 北京科拓恒通生 ...

证券之星消息，8月4日化学制品板块较上一交易日上涨0.49%，松井股份领涨。当日上证指数报收于 3583.31，上涨0.66%。深证成指报收于11041.56，上涨0.46%。化学制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688157 | 松井股份 | 41.15 | 11.19% | 7.54万 | 2.99亿 | | 300858 | 科拓生物 | 22.66 | 11.08% | 40.35万 | 8.70亿 | | 603683 | 晶华新材 | 23.76 | 8.49% | 15.95万 | 3.73亿 | | 002669 | 康达新材 | 13.68 | 7.04% | - 43.31万 | 5.88亿 | | 300535 | 达威股份 | 18.45 | 5.91% | 6.77万 | 1.22亿 | | 603790 | 雅运股份 | 18.97 | 5.39% | 4.22万 | 7839.29万 | | 002915 | 中欣氟材 | 2 ...

天坛生物直线涨停，科拓生物、南模生物、赛伦生物涨超10%，沃森生物、安旭生物等跟涨。 (本文来自第一财经) ...

Market Overview - As of August 1, the Shanghai Composite Index closed at 3559.95 points, with a decline of 0.37%. The Shenzhen Component Index closed at 10991.32 points, down 0.17%, and the ChiNext Index closed at 2322.63 points, decreasing by 0.24% [1]. Trading Volume Analysis - A total of 1503 stocks saw an increase in average transaction volume, with 31 stocks experiencing a rise of over 50%. Conversely, 3051 stocks reported a decrease in average transaction volume [1]. - Notable stocks with significant increases in average transaction volume include Kecuan Technology, Shenghui Integration, and Zhengzhong Design [1]. Active Stocks by Transaction Volume - The stocks with the highest increase in average transaction volume on August 1 include: - Kecuan Technology: 9.99% increase, average transaction volume of 1014 shares, up 193.10% [3]. - Shenghui Integration: 10.00% increase, average transaction volume of 672 shares, up 191.70% [3]. - Zhengzhong Design: 10.00% increase, average transaction volume of 2134 shares, up 168.74% [3]. Active Stocks by Transaction Count - The stocks with the highest increase in transaction count on August 1 include: - Anzheng Fashion: -1.69% change, with 68,433 transactions, up 1618.56% [2]. - Yingweike: 2.04% change, with 218,079 transactions, up 1082.38% [2]. - Zhongjiabo Chuang: -3.90% change, with 48,487 transactions, up 656.19% [2]. Stocks with Significant Increases in Both Volume and Count - Kecuan Technology stands out with a 9.99% increase, an average transaction volume of 1014 shares (up 193.10%), and a transaction count of 16,921 (up 126.52%) [4]. - Other notable stocks include: - Jiejia Weichuang: 20.00% increase, average transaction volume of 838 shares (up 130.45%), and 57,709 transactions (up 121.19%) [4]. - Riyi Electronics: 10.01% increase, average transaction volume of 846 shares (up 113.00%), and 25,112 transactions (up 161.72%) [4].